Allogeneic bone marrow transplantation is an effective treatment for acute lymphoblastic leukemia (ALL). 1 This efficacy is, in part, mediated by graft-versus-leukemia T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for effects (GVL). 2,3 GVL is greatest in patients with acute or chronic graft-versus-host disease (GVHD). T cells are graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine important in GVHD; 4 removing T cells from donor bone marrow greatly reduces the incidence and severity of whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage GVHD but increases the relapse risk. Different leukemias respond differently to GVL. The rea-ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa + ) (n = 716) transson for this is uncertain. Molecules on the surface of leukemia cells may determine susceptibility to GVL. 6 In experiplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling mental models, major histocompatibility complex (MHC) class I expression is needed for a CD8 + T lymphocyte donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards response whereas MHC class II is required for both initiating the immune response and serving as a target for cytoregression models were used to determine the relative risk (RR) of relapse in patients with acute (grades IItoxic CD4 + T lymphocytes. [7][8] [9] [10] [11] Experimental data suggest that alloreactive CD4 + lymphocytes are able to kill leuke-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent mia cells. 12, 13 In ALL, class II antigen expression (HLA-DR) differs significantly among leukemia phenotypes; it is covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased highest in B lineage ALL and less or absent in T lineage ALL. [14] [15] [16] [17] [18] It is thus plausible that the antileukemia effect relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse of GVHD might occur preferentially in the HLA class IIbearing B lineage leukemias. The object of this study was for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Correspondto address this question by comparing the effects of GVHD on relapse rates in B lineage and T lineage ALL. ing relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probMaterials and methods able differences in HLA-class II antigen expression. Keywords: ALL; bone marrow transplantation; graftPatients versus-leukemia; T lineage; B lineage Between 1982Between and 1992Between , 1955 
Different leukemias respond differently to GVL. The rea-ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa + ) (n = 716) transson for this is uncertain. Molecules on the surface of leukemia cells may determine susceptibility to GVL. 6 In experiplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling mental models, major histocompatibility complex (MHC) class I expression is needed for a CD8 + T lymphocyte donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards response whereas MHC class II is required for both initiating the immune response and serving as a target for cytoregression models were used to determine the relative risk (RR) of relapse in patients with acute (grades IItoxic CD4 + T lymphocytes. [7] [8] [9] [10] [11] Experimental data suggest that alloreactive CD4 + lymphocytes are able to kill leuke-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent mia cells. 12, 13 In ALL, class II antigen expression (HLA-DR) differs significantly among leukemia phenotypes; it is covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased highest in B lineage ALL and less or absent in T lineage ALL. [14] [15] [16] [17] [18] It is thus plausible that the antileukemia effect relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse of GVHD might occur preferentially in the HLA class IIbearing B lineage leukemias. Tables 1 and 2. group until the onset of GVHD at which time they were switched to the 'GVHD' group. Time to onset of GVHD Outcomes was determined as time to onset of acute GVHD or time to chronic GVHD, whichever came first. Models entering The primary endpoint was the relative leukemia relapse risk in patients with vs those without GVHD. Acute GVHD was acute and chronic GVHD as separate time-dependent covariates were also constructed. Results were similar and defined as moderate to severe (grades II-IV) disease using published criteria; 19 patients surviving у21 days with are not presented. Patients transplanted in first and second CR were analyzed separately. Models included patient-, engraftment were considered at risk. Chronic GVHD was defined by published criteria; 20 patients surviving у90 days disease-and transplant-related variables that were significantly (P Ͻ 0.05) associated with relapse. Proportional hazpost-transplant with engraftment were considered at risk. Relapse was defined as hematologic or clinical recurrence ards were tested using a time-dependent covariate model. Summary survival curves were calculated using the in any site; patients in continuous complete remission were censored at death or, for survivors, at the end of followKaplan-Meier method. The log-rank test was used for univariate comparisons. up. Leukemia-free survival was defined as survival in continuous complete remission; relapse and death from causes other than leukemia were considered treatment failures whereas patients alive and in remission were censored at Results the end of follow-up. Table 1 shows patient-, disease-and transplant-related variables by ALL phenotype for patients transplanted in first Statistical methods CR. Statistically significant differences between T lineage and B lineage ALL were noted in patient age, white blood Patient-, disease-and treatment-related variables in Tables  1 and 2 were compared using the 2 test for discrete varicell count at diagnosis, pretransplant central nervous system involvement, presence of Philadelphia chromosome and ables or the Kruskall-Wallis test for continuous variables. Cox proportional hazards regression models using a forKarnofsky performance score. Table 2 shows patient-, disease-and transplant-related variables by ALL phenotype in ward stepwise selection procedure were used to determine the relative risk of relapse in patients with acute or chronic patients transplanted in second CR. Statistically significant differences between T lineage and B lineage ALL were GVHD vs patients without GVHD, entering grades II-IV Table 1 Characteristics of patients receiving HLA-identical sibling transplants for ALL in first remission BMT = bone marrow transplantation; Cy = cyclophosphamide; TBI = total body irradiation; CSA = cyclosporine; MTX = methotrexate. Table 2 Characteristics of patients receiving HLA-identical sibling transplants for ALL in second remission (1) BMT = bone marrow transplantation; Cy = cyclophosphamide; TBI = total body irradiation; CSA = cyclosporine; MTX = methotrexate.
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noted in patient age, sex, white cell count at diagnosis, durpatients without GVHD is set to 1.0 in all comparisons. ation of first remission, interval from diagnosis to transThere is a statistically significant reduction in the relapse plant, Karnofsky performance score and donor-recipient risk associated with GVHD in both T lineage ALL (0.34; sex-match. P = 0.005) and B lineage ALL (0.44; P = 0.002) trans- Table 3 shows the probabilities (Ϯ 95% confidence planted in first CR and in T lineage (0.54; P = 0.05) and interval) of acute and chronic GVHD by ALL phenotype B lineage ALL (0.61; P = 0.01) transplanted in second CR. for patients transplanted in first and second CR. There were
The magnitude of reduction in relapse risk by GVHD was no significant differences in incidences or severity of acute similar for T lineage and B lineage ALL transplanted in or chronic GVHD after transplants for T lineage vs B lineither first CR or second CR. There were no significant eage ALL. Figures 1 and 2 depict probabilities of relapse interactions between patient-, disease-and transplantby ALL phenotype. related characteristics and the reduction in relapse risk by Table 4 shows the results of multivariate analyses. For GVHD. purposes of comparability, the relative risk of relapse in Table 3 Probability (Ϯ95% confidence interval) of acute and chronic GVHD in patients receiving HLA-identical sibling transplants for ALL in first complete remission by ALL phenotype Patients transplanted in second remission had higher relapse rates than those transplanted in first remission, as is reported in most studies of transplants for leukemia. The first remission cohort likely includes some patients already cured by chemotherapy. Among patients transplanted in first remission, B lineage ALL was associated with a higher relapse rate than T lineage ALL; the opposite was observed in patients transplanted in second remission. Differences in relapse risk in T vs B lineage ALL, especially in first remission, may result from many factors. These include differences in prognostic variables such as age, cytogenetics, white cell count, central nervous system disease, first influenced by leukemia phenotype. In many centers, T cell phenotype alone is a criterion for transplant in first remission. In contrast, patients with B lineage ALL are considered for a first remission transplant only if other risk factors such as older age, high leukocyte count or abnormal cytogenetics are present. The object of this study was not to compare absolute rates of relapse in T vs B lineage ALL. Rather, we focused on GVL effects, specifically whether GVHD decreased relapse risk to the same extent in T lineage and B lineage ALL. To avoid confounding by other factors, we used multivariate models adjusting for other prognostic factors and considered the relative risk of relapse in patients with GVHD vs without GVHD in each lineage separately. This relative risk is a measure of the strength of the GVHD-associated GVL effect. It was similar in T lineage and B lineage ALL.
Effector mechanisms of GVL and GVHD are complex There is a correlation between the proliferative response of alloactivated lymphocytes and the expression of HLA-DR Discussion molecules by stimulatory leukemia cells and this response is inhibited by monoclonal antibodies to MHC class II molThere were two major findings in this study. First, there is ecules. 27 We therefore hypothesized that leukemias a GVHD-associated GVL effect of allogeneic transplants expressing class II MHC molecules might be more suscepin ALL, indicated by lower relapse risks in patients with tible to GVL than leukemias failing to do so. However, the clinically manifest acute and/or chronic GVHD. This condata presented here do not show a difference in the GVHDfirms previous findings. [2] [3] [4] Second, the magnitude of the associated decreases in relapse risk between T lineage and antileukemia effect of GVHD is similar in T and B lin-B lineage ALL. Unfortunately, HLA-class II antigen eage ALL.
expression was not reported in the cases analyzed, although GVL effects are defined as antileukemia activity of it may be reasonable to assume that most B lineage leuketransplants not resulting from pretransplant cytotoxic mias and few T lineage leukemias in this study expressed therapy. [2] [3] [4] [22] [23] [24] Evidence for GVL includes lower relapse HLA class II (HLA-DR) molecules. [14] [15] [16] [17] [18] Quantitative analyrates in patients with vs without GVHD; 3 lower relapse sis of class II expression would be helpful to elucidate this rates after HLA-identical sibling vs identical twin transquestion further. We confirm an antileukemic effect of plants; 3 higher relapse rates after T cell-depleted trans-GVHD in ALL that is of similar strength in T lineage and plants; 5 and remission induction after donor leukocyte B lineage ALL. infusion in patients with leukemia relapsing post-transplant. 25 The magnitude of GVL effects is greatest in chronic 157  Table 4 Multivariate analysis of relapse in patients with and without GVHD, by ALL phenotype after bone marrow transplantation from HLA-identical sib-
